Adaptimmune Therapeutics PLC ADR ADAP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADAP is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.90
- Day Range
- $0.92–1.10
- 52-Week Range
- $0.42–2.05
- Bid/Ask
- $0.98 / $0.98
- Market Cap
- $249.61 Mil
- Volume/Avg
- 1.5 Mil / 1.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 449
- Website
- https://www.adaptimmune.com
Valuation
|
Metric
|
ADAP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.17 |
Price/Sales | 3.00 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADAP
|
|---|---|
Quick Ratio | 2.66 |
Current Ratio | 2.85 |
Interest Coverage | — |
Quick Ratio
ADAP
Profitability
|
Metric
|
ADAP
|
|---|---|
Return on Assets (Normalized) | −39.19% |
Return on Equity (Normalized) | −143.62% |
Return on Invested Capital (Normalized) | −115.52% |
Return on Assets
ADAP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xpjmdjqwr | Tjl | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fkxwctbyx | Dkvqq | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hcqqfcv | Bfgff | $98.1 Bil | |
MRNA
| Moderna Inc | Nlymmqygq | Fhql | $39.1 Bil | |
ARGX
| argenx SE ADR | Mjqsxtn | Pwzjl | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Bnxgszmp | Gfbf | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zqlcmff | Pncxls | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lrtpgtf | Szxlgd | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zqyjpnkvj | Cvvxys | $12.5 Bil | |
INCY
| Incyte Corp | Jdbgxvvgl | Cxgkj | $11.9 Bil |